2020-11-11T17:00:20-06:00 2019-12-31 350921680 CROWE LLP 135 N Pennsylvania Street Suite 200 Indianapolis IN 46204 990 2019-01-01 462882271 Indiana Biosciences Research Institute Inc INDI 3179833350 1210 Waterway Blvd 2000 Indianapolis IN 46202 Mark Andersen CFO 2020-11-11 true Jennifer Burke P01342224 3176321100 2019 2021-01-29 14:40:06Z X Mark Andersen 1210 Waterway Blvd 2000 Indianapolis IN 46202 27066823 false X www.indianabiosciences.org X 2013 IN THE IBRI IS AN INDEPENDENT LIFE SCIENCES INSTITUTE FOCUSED ON BOTH DISCOVERY AND APPLIED RESEARCH AIMED AT ADDRESSING MAJOR CHALLENGES TARGETING DIABETES, CARDIO-METABOLIC DISEASES, AND POOR NUTRITION. THE IBRI WORKS IN COLLABORATION WITH OTHERS PRIMARILY IN THE US MAKING RESULTS AVAILABLE TO THE PUBLIC ON A NON-DISCRIMINATORY BASIS. THE IBRI FACILITATES THE DEVELOPMENT OF INNOVATION TO AID THE STATE OF INDIANA AND ITS RESIDENTS TO IMPROVE PUBLIC HEALTH, ATTRACT TALENT AND INDUSTRY TO THE STATE, AND TO COMMERCIALIZE TECHNOLOGIES THAT MIGHT FOSTER FURTHER ECONOMIC DEVELOPMENT. 9 8 50 8 446 -2367 5478991 7915260 346883 693780 1153588 1512842 -17 -694 6979445 10121188 0 0 0 0 5270323 6063279 26128 24955 1041199 4116448 5313401 9412899 11401635 -2433454 -1280447 132734431 142532577 6371919 8238327 126362512 134294250 To become the leading independent, industry-inspired research institute in the discovery and development of innovative solutions to improve health, targeting diabetes, metabolic disease, and poor nutrition. false false 8841888 693780 THE INSTITUTE'S SCIENTIFIC RESEARCH FOCUSES ON DISCOVERING INNOVATIVE SOLUTIONS FOR DISEASES, INCLUDING THE INTERRELATED METABOLIC DISORDERS OF CARDIOVASCULAR DISEASE, DIABETES, OBESITY, AND NUTRITION. 8841888 true true false true false false false false true true true false false false true true false false true true false false true false false false false false true false false false false false false false false true false false false false true true false false false true 37 0 true 50 true true true false false false false false false false false false false false X 9 8 false false false false false false false true true false false true true true true true true true true true true IN X Mark Andersen 3179833350 1210 Waterway Blvd INDIANAPOLIS IN 46202 DANIEL F EVANS JR EXECUTIVE CHAIR 30.0 X X 200000 0 0 RAINER FISCHER PhD CEO & CSIO (Partial Year) 40.0 0.5 X X 787753 0 33738 WAYNE BURRIS TREASURER 0.5 X X 0 0 0 DANIEL PETERSON DIRECTOR 0.5 X 0 0 0 DARREN J CARROLL DIRECTOR (partial year) 0.5 X 0 0 0 DAVID L JOHNSON SECRETARY & VICE CHAIR (partial year) 0.5 X 0 0 0 Jerre Stead Director 0.5 X 0 0 0 JOHN C LECHLEITER PhD DIRECTOR 0.5 X 0 0 0 JON C SERBOUSEK DIRECTOR 0.5 X 0 0 0 KRISTINA BOX MD DIRECTOR 0.5 X 0 0 0 NORA DOHERTY DIRECTOR (PARTIAL YEAR) 0.5 X 0 0 0 PATRICIA MARTIN DIRECTOR 0.5 X 0 0 0 STEVE WEBB PhD DIRECTOR (partial year) 0.5 X 0 0 0 WILLIAM B STEPHAN DIRECTOR 0.5 X 0 0 0 JOHN (JAY) M MCGILL PhD CHIEF OPERATING OFFICER 40.0 0.5 X 370584 0 33215 MARK ANDERSEN CHIEF FINANCIAL OFFICER 40.0 X 310579 0 33081 DANIEL ROBERTSON PhD RESEARCH FELLOW & VP OF DIGITAL TECHNOLOGY 40.0 X 247324 0 31531 STEPHANIE GRINAGE VICE PRESIDENT FOR ADVANCEMENT 40.0 X 270585 0 23850 VIDADI YUSIBOV PhD SENIOR RESEARCH FELLOW 40.0 X 304372 0 25824 BRIAN FILLENWARTH FINANCIAL CONTROLLER 40.0 X 168477 0 26055 MICHAEL PUGIA PhD RESEARCH FELLOW 40.0 X 245056 0 25786 MUSTAPHA MOUSSAIF PhD SR STAFF SCIENTIST 40.0 X 124160 0 21365 STEVEN A HANEY RESEARCH DIRECTOR 40.0 X 187636 0 16684 VICTOR J WROBLEWSKI RESEARCH DIRECTOR 40.0 X 190000 0 13080 3406526 0 284209 16 false true false Strategic Investment Group 1001 Nineteenth Street North 16th Floor Arlington VA 22209 Investment Services 450106 Indiana University-Purdue University Dept 78920 PO Box 78000 Detroit MI 482780920 Research Services 286850 RadCube 9449 Priority Way Indianapolis IN 46240 Research Services 145312 Odgers Berndtson 140 E 45th Street 44th Floor New York NY 10017 Recruiting 142777 BlackInk IT 1101 E 16th Street Suite 300 Indianapolis IN 46202 IT Support 126045 5 0 0 0 0 5000000 2915260 251898 7915260 Research Collaboration 541700 691610 691610 Research Services 541700 2170 2170 0 0 0 0 693780 1345876 446 1345430 75839 76533 -694 0 -694 -694 17036068 16843160 25942 192908 -25942 166966 0 166966 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 10121188 693780 446 1511702 0 0 0 0 0 0 0 0 2527788 1359884 464183 703721 0 0 0 0 2674077 2307327 366750 0 253939 208230 33012 12697 317666 232017 52662 32987 289809 237644 37675 14490 237812 153597 61701 22514 30799 30799 56025 28525 27500 24955 24955 540735 405552 81110 54073 493161 428524 46154 18483 131522 64558 32277 34687 149034 127040 9463 12531 308249 172385 123500 12364 0 0 0 0 235318 155554 74446 5318 182843 141295 16587 24961 0 0 0 0 9268 7645 1223 400 162836 122127 24425 16284 0 0 0 0 1029081 980921 28896 19264 39695 30565 5160 3970 Lab Expenses 1707023 1707023 0 0 0 0 0 0 11401635 8841888 1518548 1041199 0 0 0 0 0 0 647546 2976766 16058145 6100000 234152 194067 0 0 0 0 0 0 0 0 75509 130802 5854465 2926956 2843510 2927509 53323812 62575079 59551757 67628354 0 0 0 0 0 132734431 142532577 1772728 1132916 300000 300000 207686 1293247 0 0 0 0 0 0 4009944 5512164 0 0 81561 0 6371919 8238327 X 99716642 101064618 26645870 33229632 0 0 0 0 0 0 126362512 134294250 132734431 142532577 -1280447 9212185 0 0 0 0 X false true X true false X 61500500 62022718 451282 5478991 7915260 137368751 0 0 0 0 0 0 0 0 0 0 0 0 61500500 62022718 451282 5478991 7915260 137368751 101656372 35712379 51859 762159 1240224 1221716 1345876 4621834 0 0 0 229 0 229 0 0 0 0 0 0 141990814 1249341 0.2515 X Schedule A, Part II, Line 17a 10% FACTS & CIRCUMSTANCES TEST - 2019 INDIANA BIOSCIENCES RESEARCH INSTITUTE, INC. (IBRI) IS A RESEARCH INSTITUTE FOCUSED ON DISCOVERING INNOVATIVE SOLUTIONS FOR DISEASES, INCLUDING THE INTERRELATED METABOLIC DISORDERS OF CARDIOVASULAR DISEASE, DIABETES, OBESITY, AND NUTRITION. IBRI MEETS THE 10% FACTS AND CIRCUMSTANCES TEST AND QUALIFIES AS A PUBLICLY SUPPORTED ORGANIZATION. TREAS. REG. SECTION 1.170A-9(f)(3) PROVIDES THAT IN ORDER TO MEET THE "FACTS AND CIRCUMSTANCES" TEST, AN ORGANIZATION MUST NORMALLY RECEIVE SUBSTANTIAL SUPPORT (MORE THAN 10%) FROM CONTRIBUTIONS FROM GOVERNMENTAL UNITS, THE GENERAL PUBLIC, OR A COMBINATION OF THESE SOURCES. THE FOLLOWING FACTORS ESTABLISH THE PUBLICLY SUPPORTED NATURE OF IBRI UNDER THE FACTS-AND-CIRCUMSTANCES TEST: IBRI RECEIVES SUBSTANTIAL PUBLIC SUPPORT. IBRI TO DATE HAS RECEIVED $45M FROM THE STATE OF INDIANA ALONE OUT OF ITS TOTAL SUPPORT OF APPROXIMATELY $168M. ITS CALCULATED PUBLIC SUPPORT PERCENTAGE ACCORDING TO SCHEDULE A, PART II IS 25.15%, WHICH IS SUBSTANTIALLY ABOVE THE 10% THRESHOLD. IBRI MAINTAINS A CONTINUOUS AND BONA FIDE PROGRAM TO ATTRACT NEW PUBLIC AND GOVERNMENTAL SUPPORT. THE FUNDS RAISED TO ESTABLISH THE IBRI INCLUDED $45M IN "SEED" FUNDING FROM THE STATE OF INDIANA. SINCE ITS INCEPTION, A BROADER SET OF GOVERNMENTAL AND NON-GOVERNMENTAL CONTRIBUTORS TO IBRI CONTINUES TO GROW AS IBRI EXPANDS COLLABORATIONS, ADDS NEW SCIENTISTS, VALIDATES ITS MODEL AND PRODUCES POSITIVE RESULTS/IMPACT. IBRI CONTINUES TO SEEK ADDITIONAL GOVERNMENTAL FUNDING, INCLUDING THROUGH THE NATIONAL INSTITUTES OF HEALTH (NIH). RECEIPT OF NIH FUNDING IS A LENGTHY PROCESS AS IT TAKES TIME TO GENERATE DATA, FILE GRANT APPLICATIONS, AND ULTIMATELY RECEIVE FUNDING APPROVAL. IBRI CARRIES ON ACTIVITIES DESIGNED TO ATTRACT SUPPORT FROM THE GOVERNMENT OR PUBLIC SOURCES. IBRI CARRIES ON THE TYPE OF ACTIVITIES THAT ARE DESIGNED TO ATTRACT GOVERNMENT AND PUBLIC SUPPORT BECAUSE ITS RESEARCH AIMS TO DISCOVER INNOVATIVE SOLUTIONS FOR DISEASES, INCLUDING THE INTERRELATED METABOLIC DISORDERS OF CARDIOVASULAR DISEASE, DIABETES, OBESITY, AND NUTRITION. INDIANA RANKS #9 ON THE LIST OF STATES WITH THE HIGHEST RATE OF DIABETES, ACCORDING TO THE ROBERT WOOD JOHNSON FOUNDATION. AND, INDIANA IS RANKED TOWARD THE BOTTOM OF THE LIST (#41) FOR OVERALL HEALTH, ACCORDING TO UNITED HEALTH FOUNDATION'S AMERICA'S HEALTH RANKINGS. THEREFORE, THE ACTIVITIES OF IBRI TOWARD IMPROVING HEALTH ARE OF SIGNIFICANT INTEREST TO THE STATE OF INDIANA AND BEYOND. IBRI HAS A REPRESENTATIVE GOVERNING BODY. FROM INCEPTION THE BOARD OF DIRECTORS OF THE ORGANIZATION HAS INCLUDED A STATE OFFICIAL HAVING SPECIAL KNOWLEDGE OR EXPERTISE TO REPRESENT THE PUBLIC INTEREST. DURING 2019 THE BOARD OF DIRECTORS OF IBRI INCLUDED KRISTINA BOX, MD, FACOG, INDIANA STATE HEALTH COMMISSIONER. IBRI PUBLISHES ITS RESEARCH FINDINGS TO BENEFIT PUBLIC HEALTH. THE FACT THAT AN ORGANIZATION IS A RESEARCH INSTITUTION THAT REGULARLY PUBLISHES SCHOLARLY STUDIES THAT ARE WIDELY USED BY COLLEGES AND UNIVERSITIES OR BY MEMBERS OF THE GENERAL PUBLIC IS EVIDENCE THAT THE ORGANIZATION IS "PUBLICLY SUPPORTED." IBRI MAKES RESEARCH RESULTS AVAILABLE TO THE PUBLIC ON A NON-DISCRIMINATORY BASIS TO BENEFIT PUBLIC HEALTH AND FURTHER THE SCIENTIFIC BODY OF KNOWLEDGE. IBRI IS ACCOUNTABLE AS A CONDITION OF ITS GRANTS. IBRI RECEIVES SIGNIFICANT FUNDING FROM THE STATE OF INDIANA, AND THE TERMS OF THE APPLICABLE GRANT AGREEMENTS HOLD IBRI ACCOUNTABLE AS A CONDITION OF SUCH GRANTS. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false false true 56025 56025 false Schedule C, Part II-B, Line 1 DETAILED DESCRIPTION OF THE LOBBYING ACTIVITY MEMBERS OF IBRI MANAGEMENT MET WITH INDIANA LEGISLATORS AND STAFF FOR THE PURPOSE OF SOLICITING GOVERNMENTAL GRANTS TO FURTHER THE ORGANIZATION'S EXEMPT PURPOSE. IBRI IS A MEMBER OF THE BIOTECHNOLOGY INNOVATION ORGANIZATION AND ASSOCIATION OF INDEPENDENT RESEARCH ASSOCIATIONS. BOTH ORGANIZATIONS USE A PORTION OF MEMBERSHIP FEES FOR LOBBYING ACTIVITIES IN AN EFFORT TO ADVANCE BIOSCIENCE RESEARCH INTERESTS. 111610169 16576898 10750966 7700000 2300000 128938033 107715560 5000000 -1105391 111610169 95933567 5000000 6781993 107715560 0 95046251 887316 0 0 0 95933567 0 0 0.7915 0.1941 0.0144 false false 0 0 0 0 0 0 0 0 614945 614775 170 0 5117433 2202536 2914897 0 122087 109645 12442 2927509 Commingled Investment Funds 66362954 F Equity Investment 1265400 F 67628354 Deferred Rent Incentive 0 0 X 18895116 9212185 0 0 0 9212185 9682931 540731 -102474 438257 10121188 10963378 0 0 0 0 0 10963378 540731 -102474 438257 11401635 Schedule D, Part V, Line 4 Intended uses of endowment funds THE ENDOWMENT FUNDS ARE INTENDED TO SUPPORT THE ONGOING OPERATIONS OF THE IBRI. Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote The Institute is exempt from income taxes under §501(c)(3) of the U.S. Internal Revenue Code and is classified as a public charity under §509(a)(1) and §170(b)(1)(A)(vi). The Institute has adopted accounting guidance related to accounting for uncertainty in income taxes. This guidance requires the Institute to recognize a tax benefit only if it is more likely than not the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50 percent likely of being realized on examination. For tax positions not meeting the more-likely-than-not test, no tax benefit is recorded. The Institute has examined this issue and has determined there are no material contingent liabilities or questionable tax positions. The Institute does not expect the total amount of unrecognized tax benefits to significantly change in the next 12 months. The Institute recognizes interest and/or penalties related to income tax matters in income tax expense. The Institute did not have any amount accrued for interest and penalties at December 31, 2019 or 2018. Schedule D, Part XI, Line 4(b) Other revenues in form 990 not in audited financial statements Rent Revenue included as Occupancy offset - -76532 Loss on Disposal - -25942 Schedule D, Part XII, Line 4(b) Other expenses in form 990 not in audited financial statements Rent Expense included within Revenues - -76532 Loss on Disposal - -25942 Europe (Including Iceland and Greenland) 0 1 Program Services SCIENTIFIC ADVISORY SERVICES 27675 Europe (Including Iceland and Greenland) 0 0 Investments n/a 100000 Central America and the Caribbean 0 0 Investments n/a 17615000 East Asia and the Pacific 0 0 Investments n/a 129500 0 1 0 0 0 1 17872175 0 17872175 true false true true false false X X X true JOHNSON GROSSNICKLE & ASSOC 29 SOUTH PARK BLVD GREENWOOD IN 46143 CONSULTING false 0 14610 -14610 0 14610 -14610 CA CO CT FL GA AL HI IL IN KS KY ME AK MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA AR WA WV WI X X X X X false false false false false false false false false DANIEL F EVANS JR EXECUTIVE CHAIR 200000 0 0 0 0 0 0 0 0 0 200000 0 0 0 RAINER FISCHER PhD CEO & CSIO (Partial Year) 690497 0 97256 0 0 0 16800 0 16938 0 821491 0 0 0 MARK ANDERSEN CHIEF FINANCIAL OFFICER 268256 0 42323 0 0 0 16666 0 16415 0 343660 0 0 0 JOHN (JAY) M MCGILL PhD CHIEF OPERATING OFFICER 314475 0 56109 0 0 0 16800 0 16415 0 403799 0 0 0 DANIEL ROBERTSON PhD RESEARCH FELLOW & VP OF DIGITAL TECHNOLOGY 247324 0 0 0 0 0 15137 0 16394 0 278855 0 0 0 VIDADI YUSIBOV PhD SENIOR RESEARCH FELLOW 304372 0 0 0 0 0 16800 0 9024 0 330196 0 0 0 STEPHANIE GRINAGE VICE PRESIDENT FOR ADVANCEMENT 256177 0 14408 0 0 0 12000 0 11850 0 294435 0 0 0 MICHAEL PUGIA PhD RESEARCH FELLOW 245056 0 0 0 0 0 15450 0 10336 0 270842 0 0 0 BRIAN FILLENWARTH FINANCIAL CONTROLLER 155153 0 13324 0 0 0 10333 0 15722 0 194532 0 0 0 STEVEN A HANEY RESEARCH DIRECTOR 187636 0 0 0 0 0 10450 0 6234 0 204320 0 0 0 VICTOR J WROBLEWSKI RESEARCH DIRECTOR 190000 0 0 0 0 0 11400 0 1680 0 203080 0 0 0 X 1 251898 Market value 0 false true false Schedule M, Part I Explanations of reporting method for number of contributions Securities - Publicly traded - number of contributions Form 990, Part VI, Line 1a Delegate broad authority to a committee THE BOARD OF DIRECTORS DELEGATES BROAD AUTHORITY TO AN EXECUTIVE COMMITTEE TO ACT ON THE ORGANIZATION'S BEHALF. THE COMMITTEE IS ESTABLISHED BY THE BOARD TO EXERCISE THE POWERS OF THE BOARD IN RELATED TO MATTERS THAT ARISE BETWEEN REGULARLY SCHEDULED BOARD MEETINGS AND/OR WHEN IT IS NOT PRACTICAL OR FEASIBLE FOR THE BOARD TO MEET. THE COMMITTEE IS COMPRISED OF THE Executive chair AND 4 DIRECTORS. Form 990, Part VI, Line 11b Review of form 990 by governing body IBRI'S TAX RETURN WAS PREPARED BY THE FINANCE DEPARTMENT AND REVIEWED BY AN INDEPENDENT ACCOUNTING FIRM AND BY THE IBRI'S LEGAL COUNSEL. SUBSEQUENTLY, A SUBSTANTIALLY COMPLETE FORM 990 AND SUPPLEMENTAL SCHEDULES WERE PRESENTED TO THE FULL BOARD OF DIRECTORS FOR REVIEW AND COMMENT PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. Form 990, Part VI, Line 12c Conflict of interest policy It is the policy of IBRI and its Board of Directors that the Corporation's directors, officers, and employees carry out their respective duties in a fashion that avoids actual, potential, or perceived conflicts of interest. IBRI's directors, officers, and employees shall have the continuing, affirmative duty to report any personal ownership, interest, or other relationship that might affect their ability to exercise impartial, ethical, and business-based judgments in fulfilling their responsibilities to the organization. Each year directors, officers, and employees acknowledge and agree that they have a duty to avoid business, financial or other interests or relationships that conflict with the interests of the Institute or that divide their loyalty to the Institute. Any activity that appears to present a conflict must be disclosed to the Institute and must be avoided or terminated unless the Institute in its sole discretion determines the activity is not harmful to the Institute or otherwise improper. The Board of Directors shall be responsible for oversight of all disclosures or failures to disclose and for taking appropriate action in the case of any actual or potential conflict of interest transaction. Form 990, Part VI, Line 15a Process to establish compensation of top management official A COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS DETERMINES COMPENSATION FOR THE CEO USING COMPARABILITY DATA AND COMPENSATION SURVEYS. THE BOARD CONTEMPORANEOUSLY DOCUMENTS THE DELIBERATION AND DECISION OF THIS PROCESS. THIS PROCESS OCCURS ANNUALLY AND LAST OCCURRED IN September 2019. Form 990, Part VI, Line 15b Process to establish compensation of other employees A COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS DETERMINES COMPENSATION FOR THE CEO, CSIO, CHIEF OF STAFF, AND CFO USING COMPARABILITY DATA AND COMPENSATION SURVEYS. THE BOARD CONTEMPORANEOUSLY DOCUMENTS THE DELIBERATION AND DECISION OF THIS PROCESS. THIS PROCESS OCCURS ANNUALLY AND LAST OCCURRED IN September 2019. Form 990, Part VI, Line 19 Required documents available to the public THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE UPON WRITTEN REQUEST. 16 TECH COMMUNITY CORPORATION 300 NORTH MERIDIAN STREET SUITE 950 INDIANAPOLIS IN 46204 810853467 FOSTER ECONOMIC DEVELOPMENT IN THE CITY OF INDIANAPOLIS IN 501(c)(3) Type I NA false Sierra Diagnostics Inc 1345 W 16th St Ste 300 Indianapolis IN 46202 851059747 Lab Instrument Manufacturing IN Indiana Biosciences Research Institute C Corporation 0 0 true false false false false false false false false false false false false false false false false false false false